Cutler Group LP Otonomy, Inc. Call Options Transaction History

Cutler Group LP

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2018 Aug 10, 2018	SELL	$3.7 - $4.75 $28,490 - $36,575	-7,700 Reduced 98.72%	100 $0
Q1 2018 May 11, 2018	BUY	$4.05 - $6.1 $24,705 - $37,210	6,100 Added 358.82%	7,800 $0
Q4 2017 Jan 17, 2018	SELL	$2.8 - $5.55 $280,000 - $555,000	-100,000 Reduced 98.33%	1,700 $2,000
Q3 2017 Oct 17, 2017	BUY	$3.2 - $20.8 $325,440 - $2.12 Million	101,700	101,700 $4,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.